Results showed that, compared to placebo, subjects taking the black seed and astaxanthin blend reported significantly fewer upper-respiratory tract complaints and better overall well-being, as well as lower cortisol and superior microbiome indices.
Photo © iStockphoto.com/peepo
A recent study1 investigated the effects of a proprietary black seed oil, ThymoQuin, when combined with AstaPure astaxanthin in endurance runners. In the study, 32 subjects (21 male and 11 female) runners were given either a placebo of a soft-gel oil blend containing 500 mg of the black see oil with 8 mg of the astaxanthin oleoresin for four weeks. Supplementation took place three weeks prior to and one week following a marathon or half-marathon competition. Researchers collected profile of mood state (POMS) psychological assessments and health log questionnaires from subjects assessing health status and upper-respiratory tract complaints (URTCs), as well as provided saliva samples and fecal samples for measurement of cortisol and microbiome balance.
Results showed that, compared to placebo, subjects taking the black seed and astaxanthin blend reported significantly fewer URTCs and better overall well-being, as well as lower cortisol and superior microbiome indices. These results suggest that the combination of black seed oil and astaxanthin supports immune health and overall well-being following endurance training and competition by way of the microbiome.
“These results demonstrate a significant and meaningful benefit to balance the overall immune system and to aid in a better mood state,” said Morris Zelkha, CEO of TriNutra, the manufacturer of ThymoQuin, in a press release. “When the entire system is balanced, as evidenced here in the Supplement group, there is a noticeable benefit for physical health and mental wellness. This study continues to add to the arsenal of published studies demonstrating ThymoQuin’s potent and powerful effects as a stand-alone ingredient and a powerful and synergistic ingredient.”
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.